Lopinavir/Ritonavir (Kaletra)

Overview | News | Research

Overview

Medication Guide for HIV-Infected Patients on Lopinavir/Ritonavir (February 2011)
Created by Abbott Laboratories and approved by the U.S. Food and Drug Administration; includes overviews of possible adverse effects, drug interaction warnings and dosing tips.
From Abbott Laboratories
Prescribing Information for Kaletra (Lopinavir/Ritonavir) Tablets and Oral Solution (PDF) (February 2011)
From Abbott Laboratories
Drug Interactions: Kaletra (August 2004)
From Project Inform
The Debate Over Kaletra (Lopinavir/Ritonavir) "Monotherapy" (August 2004)
From amfAR, The Foundation for AIDS Research

News

Abbott Cuts Cost of AIDS Drug for Government Programs (May 10, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Lopinavir/r Oral Solution (March/April 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
U.S. Jury Rejects Glaxo Antitrust Claim vs. Abbott (March 31, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
U.S. Warns Against Abbott HIV Drug in Premature Babies (March 9, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Kaletra (Lopinavir/Ritonavir) Oral Solution Label Changes Related to Toxicity in Preterm Neonates (February 24, 2011)
From U.S. Food and Drug Administration
Indian Government Rejects Abbott's Patent Application for Second-Line ARV (January 4, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
Lopinavir/Ritonavir Approved (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
FDA Probes Risks of HIV, Prostate, Other Drugs (May 4, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Once-Daily Kaletra Dosing Approved for Treatment-Experienced Adults (April 28, 2010)
From U.S. Food and Drug Administration
Kaletra (Lopinavir/Ritonavir) Package Insert Revision Regarding Drug-Drug Interaction Information (January 29, 2010)
From U.S. Food and Drug Administration

VIEW ALL ARTICLES

Research

Clinical Trials Using Kaletra (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Pharmacokinetics and Acceptability of Lopinavir/Ritonavir Sprinkles in Children Aged 1 to 4 Years (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Lopinavir/Ritonavir Equivalent to Nevirapine in Ugandan Children (March 14, 2013)
From aidsmap.com
HIV Drug Not Tied to Premature Births (March 8, 2013)
From MedPage Today
Lopinavir/Ritonavir in Pregnancy: Results From a Systematic Review (January/February 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Simplified Protease Inhibitor Monotherapy Fails to Maintain HIV Suppression (October 26, 2012)
From HIVandHepatitis.com
Simplifying HAART Regimen Fails to Maintain HIV-1 Viral Suppression (October 23, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Novel Lopinavir/Ritonavir Sprinkle Formulation for Children in Resource-Limited Settings (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Lopinavir/Ritonavir Monotherapy in Children (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Lower Malaria Risk in Children Receiving Lopinavir/Ritonavir-Based Compared to NNRTI-Based ART (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated
	Exploring the Media Fascination With the Baby Cured of HIV

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.